Review



matrigel cultrex bio techne 3433 010 r1  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Bio-Techne corporation matrigel cultrex bio techne 3433 010 r1
    (A) Transwell assays with CXCL10 and CXCL11-supplemented T cell media at the bottom well. Inserts coated with <t>matrigel</t> were placed on top of the well and d10-12 CTLs were dispensed in the insert in drug-containing media. Vismodegib 5 μM, one independent experiment, n=5 healthy donors. Sonidegib 10 μM, one independent experiment, n=5 healthy donors. For each drug paired t-tests were performed and mean ± SD is shown. (B) Transwell assays as in (A) . Bortedella pertussis toxin (PTX) 200ng/ml, two independent experiments, n=9 healthy donors. ROCK inhibitor 10 μM, two independent experiments, n=6 healthy donors, GRK inhibitor CCG215022 0.032-0.32mM, three independent experiments, n=11 healthy donors. For each drug paired t-tests were performed and mean ± SEM is shown. (C) Representative sections of separate BCCs resected from the same cancer patient while “on” or “off” vismodegib treatment and stained with antibodies against CD3, CD8, CD4, SOX10. Nuclei were stained with DAPI. Vismodegib treatment diminished the number of T cells infiltrating the tumour. Scale bar equals 100 μm. (D) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins). Separate resected tumour specimens of the same patient (ALF006) spanning 11 years while the patient was “on” or “off” vismodegib treatment were analysed. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (E) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins) per mm 2 of stroma and tumour areas, respectively. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (F) Proximity analysis of each BCC cell to its closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ). Heatmap indicates the number of BCC tumour cells within the indicated distance brackets. n=3 BCCs “on” and n=3 BCCs “off” treatment. (G) Percentage of total BCC cells shown with regards to their closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ) adjusted for tumour load. Means of n=3 BCCs “on” and n=3 BCCs “off” treatment are shown.
    Matrigel Cultrex Bio Techne 3433 010 R1, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3433-010-R1/bio_rxiv__2024__08__14__607917-240-11-13
    Average 86 stars, based on 1 article reviews
    matrigel cultrex bio techne 3433 010 r1 - by Bioz Stars, 2026-09
    86/100 stars

    Images

    1) Product Images from "Hedgehog signaling controls cytotoxic T cell migration in the tumour microenvironment"

    Article Title: Hedgehog signaling controls cytotoxic T cell migration in the tumour microenvironment

    Journal: bioRxiv

    doi: 10.1101/2024.08.14.607917

    (A) Transwell assays with CXCL10 and CXCL11-supplemented T cell media at the bottom well. Inserts coated with matrigel were placed on top of the well and d10-12 CTLs were dispensed in the insert in drug-containing media. Vismodegib 5 μM, one independent experiment, n=5 healthy donors. Sonidegib 10 μM, one independent experiment, n=5 healthy donors. For each drug paired t-tests were performed and mean ± SD is shown. (B) Transwell assays as in (A) . Bortedella pertussis toxin (PTX) 200ng/ml, two independent experiments, n=9 healthy donors. ROCK inhibitor 10 μM, two independent experiments, n=6 healthy donors, GRK inhibitor CCG215022 0.032-0.32mM, three independent experiments, n=11 healthy donors. For each drug paired t-tests were performed and mean ± SEM is shown. (C) Representative sections of separate BCCs resected from the same cancer patient while “on” or “off” vismodegib treatment and stained with antibodies against CD3, CD8, CD4, SOX10. Nuclei were stained with DAPI. Vismodegib treatment diminished the number of T cells infiltrating the tumour. Scale bar equals 100 μm. (D) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins). Separate resected tumour specimens of the same patient (ALF006) spanning 11 years while the patient was “on” or “off” vismodegib treatment were analysed. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (E) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins) per mm 2 of stroma and tumour areas, respectively. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (F) Proximity analysis of each BCC cell to its closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ). Heatmap indicates the number of BCC tumour cells within the indicated distance brackets. n=3 BCCs “on” and n=3 BCCs “off” treatment. (G) Percentage of total BCC cells shown with regards to their closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ) adjusted for tumour load. Means of n=3 BCCs “on” and n=3 BCCs “off” treatment are shown.
    Figure Legend Snippet: (A) Transwell assays with CXCL10 and CXCL11-supplemented T cell media at the bottom well. Inserts coated with matrigel were placed on top of the well and d10-12 CTLs were dispensed in the insert in drug-containing media. Vismodegib 5 μM, one independent experiment, n=5 healthy donors. Sonidegib 10 μM, one independent experiment, n=5 healthy donors. For each drug paired t-tests were performed and mean ± SD is shown. (B) Transwell assays as in (A) . Bortedella pertussis toxin (PTX) 200ng/ml, two independent experiments, n=9 healthy donors. ROCK inhibitor 10 μM, two independent experiments, n=6 healthy donors, GRK inhibitor CCG215022 0.032-0.32mM, three independent experiments, n=11 healthy donors. For each drug paired t-tests were performed and mean ± SEM is shown. (C) Representative sections of separate BCCs resected from the same cancer patient while “on” or “off” vismodegib treatment and stained with antibodies against CD3, CD8, CD4, SOX10. Nuclei were stained with DAPI. Vismodegib treatment diminished the number of T cells infiltrating the tumour. Scale bar equals 100 μm. (D) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins). Separate resected tumour specimens of the same patient (ALF006) spanning 11 years while the patient was “on” or “off” vismodegib treatment were analysed. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (E) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins) per mm 2 of stroma and tumour areas, respectively. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (F) Proximity analysis of each BCC cell to its closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ). Heatmap indicates the number of BCC tumour cells within the indicated distance brackets. n=3 BCCs “on” and n=3 BCCs “off” treatment. (G) Percentage of total BCC cells shown with regards to their closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ) adjusted for tumour load. Means of n=3 BCCs “on” and n=3 BCCs “off” treatment are shown.

    Techniques Used: Staining, Cell Analysis

    Related Articles

    Membrane:

    Article Title: Skin basal cell carcinomas assemble a pro-tumorigenic spatially organized and self-propagating Trem2+ myeloid niche
    Article Snippet: Briefly, Millicell-CM inserts (MilliporeSigma; PICM03050) were prepared with 1 mL of an 8:1:1 ratio of Cellmatrix Type 1-A (Fujifilm; 637-00653), 10× concentrated culture media HAM’s F-12 (catalog), and reconstitution buffer. .. Small pieces of human tumor were re-suspended in 1 mL of Cultrex Reduced Growth Factor Basement Membrane Extract, Type R1 (Biotechne; 3433-010-R1) and then placed on the solidified 8:1:1 collagen matrix. .. 1 mL of PDO media in Advanced DMEM/F-12 (Gibco; 12634010), supplemented with: 50% WNT3A, RSPO1, and Noggin-conditioned media (ATCC; CRL-3276), Hepes, (1 mM; Gibco; 15630080), GlutaMAX (1×; Gibco; 35050061), N-Acetylcysteine-1 (1 mM; Sigma Aldrich; A9165-5G), penicillin/streptomycin (100 U/L; Gibco; 15140122), nicotinamide (10mM; MilliporeSigma; N3376-100G), B-27 Supplement (50×) minus vitamin A (1x; ThermoFisher; 12587010), A83-01 (0.5 μM; Tocris; 2939), Gastrin I human (10nM; MilliporeSigma; G9020-250UG), SB202190 (10 μM; MilliporeSigma; S7067-5MG), Recombinant human IL-2 (1000 units/mL; Peprotech; 200-02), Human EGF (50 ng/mL; ThermoFisher, PHG0311L), Recombinant Human M-CSF (20 ng/mL; Peprotech; 300-25).

    Article Title: Epithelial restitution in 3D - Revealing biomechanical and physiochemical dynamics in intestinal organoids via fs laser nanosurgery
    Article Snippet: Latex beads, sulfate-modified polystyrene, fluorescent red , Sigma-Aldrich , Cat# L9902. .. Cultrex Reduced Growth Factor Basement Membrane Extract (BME), Type R1 , Bio-Techne , Cat 3433-010-R1. .. Phalloidin-Atto 488 , Sigma-Aldrich , Cat# 49409.

    other:

    Article Title: Hedgehog signaling controls cytotoxic T cell migration in the tumour microenvironment
    Article Snippet: For KPCY line 2838c3 (Kerafast #EUP013-FP) cells were co-injected 1:1 with Matrigel (Cultrex, Bio-techne #3433-010-R1).



    Similar Products

    growth factor reduced cultrex bme  (R&D Systems)
    93
    R&D Systems growth factor reduced cultrex bme
    Growth Factor Reduced Cultrex Bme, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3433-010-R1/Cultrex+RGF+Basement+Membrane+Extract%2C+Type+R1/pm40408475-367-15-23
    Average 93 stars, based on 1 article reviews
    growth factor reduced cultrex bme - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    matrigel cultrex bio techne 3433 010 r1  (Bio-Techne corporation)
    86
    Bio-Techne corporation matrigel cultrex bio techne 3433 010 r1
    (A) Transwell assays with CXCL10 and CXCL11-supplemented T cell media at the bottom well. Inserts coated with <t>matrigel</t> were placed on top of the well and d10-12 CTLs were dispensed in the insert in drug-containing media. Vismodegib 5 μM, one independent experiment, n=5 healthy donors. Sonidegib 10 μM, one independent experiment, n=5 healthy donors. For each drug paired t-tests were performed and mean ± SD is shown. (B) Transwell assays as in (A) . Bortedella pertussis toxin (PTX) 200ng/ml, two independent experiments, n=9 healthy donors. ROCK inhibitor 10 μM, two independent experiments, n=6 healthy donors, GRK inhibitor CCG215022 0.032-0.32mM, three independent experiments, n=11 healthy donors. For each drug paired t-tests were performed and mean ± SEM is shown. (C) Representative sections of separate BCCs resected from the same cancer patient while “on” or “off” vismodegib treatment and stained with antibodies against CD3, CD8, CD4, SOX10. Nuclei were stained with DAPI. Vismodegib treatment diminished the number of T cells infiltrating the tumour. Scale bar equals 100 μm. (D) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins). Separate resected tumour specimens of the same patient (ALF006) spanning 11 years while the patient was “on” or “off” vismodegib treatment were analysed. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (E) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins) per mm 2 of stroma and tumour areas, respectively. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (F) Proximity analysis of each BCC cell to its closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ). Heatmap indicates the number of BCC tumour cells within the indicated distance brackets. n=3 BCCs “on” and n=3 BCCs “off” treatment. (G) Percentage of total BCC cells shown with regards to their closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ) adjusted for tumour load. Means of n=3 BCCs “on” and n=3 BCCs “off” treatment are shown.
    Matrigel Cultrex Bio Techne 3433 010 R1, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3433-010-R1/bio_rxiv__2024__08__14__607917-240-11-13
    Average 86 stars, based on 1 article reviews
    matrigel cultrex bio techne 3433 010 r1 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    matrigel  (R&D Systems)
    93
    R&D Systems matrigel
    (A) Transwell assays with CXCL10 and CXCL11-supplemented T cell media at the bottom well. Inserts coated with <t>matrigel</t> were placed on top of the well and d10-12 CTLs were dispensed in the insert in drug-containing media. Vismodegib 5 μM, one independent experiment, n=5 healthy donors. Sonidegib 10 μM, one independent experiment, n=5 healthy donors. For each drug paired t-tests were performed and mean ± SD is shown. (B) Transwell assays as in (A) . Bortedella pertussis toxin (PTX) 200ng/ml, two independent experiments, n=9 healthy donors. ROCK inhibitor 10 μM, two independent experiments, n=6 healthy donors, GRK inhibitor CCG215022 0.032-0.32mM, three independent experiments, n=11 healthy donors. For each drug paired t-tests were performed and mean ± SEM is shown. (C) Representative sections of separate BCCs resected from the same cancer patient while “on” or “off” vismodegib treatment and stained with antibodies against CD3, CD8, CD4, SOX10. Nuclei were stained with DAPI. Vismodegib treatment diminished the number of T cells infiltrating the tumour. Scale bar equals 100 μm. (D) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins). Separate resected tumour specimens of the same patient (ALF006) spanning 11 years while the patient was “on” or “off” vismodegib treatment were analysed. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (E) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins) per mm 2 of stroma and tumour areas, respectively. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (F) Proximity analysis of each BCC cell to its closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ). Heatmap indicates the number of BCC tumour cells within the indicated distance brackets. n=3 BCCs “on” and n=3 BCCs “off” treatment. (G) Percentage of total BCC cells shown with regards to their closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ) adjusted for tumour load. Means of n=3 BCCs “on” and n=3 BCCs “off” treatment are shown.
    Matrigel, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3433-010-R1/Cultrex+RGF+Basement+Membrane+Extract%2C+Type+R1/pmc11305398-157-17-27
    Average 93 stars, based on 1 article reviews
    matrigel - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    cultrex reduced growth factor basement membrane  (R&D Systems)
    93
    R&D Systems cultrex reduced growth factor basement membrane
    (A) Transwell assays with CXCL10 and CXCL11-supplemented T cell media at the bottom well. Inserts coated with <t>matrigel</t> were placed on top of the well and d10-12 CTLs were dispensed in the insert in drug-containing media. Vismodegib 5 μM, one independent experiment, n=5 healthy donors. Sonidegib 10 μM, one independent experiment, n=5 healthy donors. For each drug paired t-tests were performed and mean ± SD is shown. (B) Transwell assays as in (A) . Bortedella pertussis toxin (PTX) 200ng/ml, two independent experiments, n=9 healthy donors. ROCK inhibitor 10 μM, two independent experiments, n=6 healthy donors, GRK inhibitor CCG215022 0.032-0.32mM, three independent experiments, n=11 healthy donors. For each drug paired t-tests were performed and mean ± SEM is shown. (C) Representative sections of separate BCCs resected from the same cancer patient while “on” or “off” vismodegib treatment and stained with antibodies against CD3, CD8, CD4, SOX10. Nuclei were stained with DAPI. Vismodegib treatment diminished the number of T cells infiltrating the tumour. Scale bar equals 100 μm. (D) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins). Separate resected tumour specimens of the same patient (ALF006) spanning 11 years while the patient was “on” or “off” vismodegib treatment were analysed. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (E) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins) per mm 2 of stroma and tumour areas, respectively. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (F) Proximity analysis of each BCC cell to its closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ). Heatmap indicates the number of BCC tumour cells within the indicated distance brackets. n=3 BCCs “on” and n=3 BCCs “off” treatment. (G) Percentage of total BCC cells shown with regards to their closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ) adjusted for tumour load. Means of n=3 BCCs “on” and n=3 BCCs “off” treatment are shown.
    Cultrex Reduced Growth Factor Basement Membrane, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3433-010-R1/Cultrex+RGF+Basement+Membrane+Extract%2C+Type+R1/pmc11204134-169-13-20
    Average 93 stars, based on 1 article reviews
    cultrex reduced growth factor basement membrane - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    basement membrane extract bme r1  (R&D Systems)
    93
    R&D Systems basement membrane extract bme r1
    (A) Transwell assays with CXCL10 and CXCL11-supplemented T cell media at the bottom well. Inserts coated with <t>matrigel</t> were placed on top of the well and d10-12 CTLs were dispensed in the insert in drug-containing media. Vismodegib 5 μM, one independent experiment, n=5 healthy donors. Sonidegib 10 μM, one independent experiment, n=5 healthy donors. For each drug paired t-tests were performed and mean ± SD is shown. (B) Transwell assays as in (A) . Bortedella pertussis toxin (PTX) 200ng/ml, two independent experiments, n=9 healthy donors. ROCK inhibitor 10 μM, two independent experiments, n=6 healthy donors, GRK inhibitor CCG215022 0.032-0.32mM, three independent experiments, n=11 healthy donors. For each drug paired t-tests were performed and mean ± SEM is shown. (C) Representative sections of separate BCCs resected from the same cancer patient while “on” or “off” vismodegib treatment and stained with antibodies against CD3, CD8, CD4, SOX10. Nuclei were stained with DAPI. Vismodegib treatment diminished the number of T cells infiltrating the tumour. Scale bar equals 100 μm. (D) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins). Separate resected tumour specimens of the same patient (ALF006) spanning 11 years while the patient was “on” or “off” vismodegib treatment were analysed. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (E) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins) per mm 2 of stroma and tumour areas, respectively. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (F) Proximity analysis of each BCC cell to its closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ). Heatmap indicates the number of BCC tumour cells within the indicated distance brackets. n=3 BCCs “on” and n=3 BCCs “off” treatment. (G) Percentage of total BCC cells shown with regards to their closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ) adjusted for tumour load. Means of n=3 BCCs “on” and n=3 BCCs “off” treatment are shown.
    Basement Membrane Extract Bme R1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3433-010-R1/Cultrex+RGF+Basement+Membrane+Extract%2C+Type+R1/pmc11166929-245-10-14
    Average 93 stars, based on 1 article reviews
    basement membrane extract bme r1 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    bme plug vascular growth assay cold liquid growth factor reduced cultrex basement membrane extract bme solution  (R&D Systems)
    93
    R&D Systems bme plug vascular growth assay cold liquid growth factor reduced cultrex basement membrane extract bme solution
    (A) Transwell assays with CXCL10 and CXCL11-supplemented T cell media at the bottom well. Inserts coated with <t>matrigel</t> were placed on top of the well and d10-12 CTLs were dispensed in the insert in drug-containing media. Vismodegib 5 μM, one independent experiment, n=5 healthy donors. Sonidegib 10 μM, one independent experiment, n=5 healthy donors. For each drug paired t-tests were performed and mean ± SD is shown. (B) Transwell assays as in (A) . Bortedella pertussis toxin (PTX) 200ng/ml, two independent experiments, n=9 healthy donors. ROCK inhibitor 10 μM, two independent experiments, n=6 healthy donors, GRK inhibitor CCG215022 0.032-0.32mM, three independent experiments, n=11 healthy donors. For each drug paired t-tests were performed and mean ± SEM is shown. (C) Representative sections of separate BCCs resected from the same cancer patient while “on” or “off” vismodegib treatment and stained with antibodies against CD3, CD8, CD4, SOX10. Nuclei were stained with DAPI. Vismodegib treatment diminished the number of T cells infiltrating the tumour. Scale bar equals 100 μm. (D) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins). Separate resected tumour specimens of the same patient (ALF006) spanning 11 years while the patient was “on” or “off” vismodegib treatment were analysed. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (E) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins) per mm 2 of stroma and tumour areas, respectively. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (F) Proximity analysis of each BCC cell to its closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ). Heatmap indicates the number of BCC tumour cells within the indicated distance brackets. n=3 BCCs “on” and n=3 BCCs “off” treatment. (G) Percentage of total BCC cells shown with regards to their closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ) adjusted for tumour load. Means of n=3 BCCs “on” and n=3 BCCs “off” treatment are shown.
    Bme Plug Vascular Growth Assay Cold Liquid Growth Factor Reduced Cultrex Basement Membrane Extract Bme Solution, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/3433-010-R1/Cultrex+RGF+Basement+Membrane+Extract%2C+Type+R1/pm38570528-256-0-16
    Average 93 stars, based on 1 article reviews
    bme plug vascular growth assay cold liquid growth factor reduced cultrex basement membrane extract bme solution - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Transwell assays with CXCL10 and CXCL11-supplemented T cell media at the bottom well. Inserts coated with matrigel were placed on top of the well and d10-12 CTLs were dispensed in the insert in drug-containing media. Vismodegib 5 μM, one independent experiment, n=5 healthy donors. Sonidegib 10 μM, one independent experiment, n=5 healthy donors. For each drug paired t-tests were performed and mean ± SD is shown. (B) Transwell assays as in (A) . Bortedella pertussis toxin (PTX) 200ng/ml, two independent experiments, n=9 healthy donors. ROCK inhibitor 10 μM, two independent experiments, n=6 healthy donors, GRK inhibitor CCG215022 0.032-0.32mM, three independent experiments, n=11 healthy donors. For each drug paired t-tests were performed and mean ± SEM is shown. (C) Representative sections of separate BCCs resected from the same cancer patient while “on” or “off” vismodegib treatment and stained with antibodies against CD3, CD8, CD4, SOX10. Nuclei were stained with DAPI. Vismodegib treatment diminished the number of T cells infiltrating the tumour. Scale bar equals 100 μm. (D) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins). Separate resected tumour specimens of the same patient (ALF006) spanning 11 years while the patient was “on” or “off” vismodegib treatment were analysed. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (E) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins) per mm 2 of stroma and tumour areas, respectively. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (F) Proximity analysis of each BCC cell to its closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ). Heatmap indicates the number of BCC tumour cells within the indicated distance brackets. n=3 BCCs “on” and n=3 BCCs “off” treatment. (G) Percentage of total BCC cells shown with regards to their closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ) adjusted for tumour load. Means of n=3 BCCs “on” and n=3 BCCs “off” treatment are shown.

    Journal: bioRxiv

    Article Title: Hedgehog signaling controls cytotoxic T cell migration in the tumour microenvironment

    doi: 10.1101/2024.08.14.607917

    Figure Lengend Snippet: (A) Transwell assays with CXCL10 and CXCL11-supplemented T cell media at the bottom well. Inserts coated with matrigel were placed on top of the well and d10-12 CTLs were dispensed in the insert in drug-containing media. Vismodegib 5 μM, one independent experiment, n=5 healthy donors. Sonidegib 10 μM, one independent experiment, n=5 healthy donors. For each drug paired t-tests were performed and mean ± SD is shown. (B) Transwell assays as in (A) . Bortedella pertussis toxin (PTX) 200ng/ml, two independent experiments, n=9 healthy donors. ROCK inhibitor 10 μM, two independent experiments, n=6 healthy donors, GRK inhibitor CCG215022 0.032-0.32mM, three independent experiments, n=11 healthy donors. For each drug paired t-tests were performed and mean ± SEM is shown. (C) Representative sections of separate BCCs resected from the same cancer patient while “on” or “off” vismodegib treatment and stained with antibodies against CD3, CD8, CD4, SOX10. Nuclei were stained with DAPI. Vismodegib treatment diminished the number of T cells infiltrating the tumour. Scale bar equals 100 μm. (D) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins). Separate resected tumour specimens of the same patient (ALF006) spanning 11 years while the patient was “on” or “off” vismodegib treatment were analysed. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (E) Numbers of CD8 T cells found in the stroma (defined as within 500 μm outwards of the tumour margin) or the tumour (defined as within the tumour margins) per mm 2 of stroma and tumour areas, respectively. n=3 “on” and n=3 “off” treatment, mean ± SD is shown. (F) Proximity analysis of each BCC cell to its closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ). Heatmap indicates the number of BCC tumour cells within the indicated distance brackets. n=3 BCCs “on” and n=3 BCCs “off” treatment. (G) Percentage of total BCC cells shown with regards to their closest neighbouring CD8 T cell (analysis workflow shown in Supp. Fig. 7C-E ) adjusted for tumour load. Means of n=3 BCCs “on” and n=3 BCCs “off” treatment are shown.

    Article Snippet: For KPCY line 2838c3 (Kerafast #EUP013-FP) cells were co-injected 1:1 with Matrigel (Cultrex, Bio-techne #3433-010-R1).

    Techniques: Staining, Cell Analysis